Stockscreener 앱 받기
1.31
24.76%
0.26
시간 외 거래:
1.33
0.02
+1.53%
Io Biotech Inc 주식(IOBT)의 최신 뉴스
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma - Seeking Alpha
IO Biotech Surges 18% on Mixed Phase 3 Trial Results: A Glimmer of Hope or Regulatory Hurdles Ahead? - AInvest
IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters
Does IO Biotech Inc. meet Warren Buffett’s criteriaFree Profit Target Calculator - thegnnews.com
IO Biotech, Inc.'s (NASDAQ:IOBT) Market Cap Dropped US$72m Last Week; Private Equity Firms Bore the Brunt - 富途牛牛
IO Biotech's Promising Phase 3 Results and FDA Engagement Bolster Buy Rating - AInvest
IO Bio plans cancer vaccine filing despite trial miss - pharmaphorum
IO Biotech's Cylembio Trial: Navigating Near-Miss Outcomes and FDA Pathways in Oncology Innovation - AInvest
IO Biotech's Near-Miss in Phase 3 Trial: A Case Study in Biotech Resilience and Strategic Value - AInvest
IO Biotech's Cylembio and KEYTRUDA Combo: A Near-Miss in Pivotal Trial—Is This a Buying Opportunity or a Cautionary Tale? - AInvest
IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint - insights.citeline.com
IO Biotech stock price target lowered to $4 at Morgan Stanley By Investing.com - Investing.com South Africa
IO Biotech stock price target lowered to $4 at Morgan Stanley - Investing.com Canada
IO Biotech's Near-Miss in Cylembio Trial: A Lesson in Incremental Progress and Long-Term Value - AInvest
Skin tight: IO Biotech melanoma phase III misses ‘by a hair’ - BioWorld MedTech
IO Biotech (IOBT.O) Suffers Intraday Freefall: What’s Behind the 33.4% Drop? - AInvest
IO Biotech to pursue cancer vaccine approval despite Phase III miss - Yahoo Finance
IO Biotech's cancer vaccine shows improvement in late-stage study goal - MSN
Promising Phase 3 Results and Strategic FDA Engagement Bolster Buy Rating for IO Biotech - TipRanks
IO Biotech sees path forward for skin cancer vaccine despite study setback - BioPharma Dive
IO Biotech Plummets 23.7%: What’s Behind the Sharp Drop? - AInvest
IO Biotech Plummets 39% on Near-Miss in Key Trial, Hints at FDA Gambit - AInvest
IO Biotech says cancer vaccine with Merck’s Keytruda outperformed in late-stage study - MSN
IO Biotech to seek FDA filing even though cancer vaccine narrowly fails pivotal skin cancer study - Endpoints News
IO Biotech's cancer vaccine Cylembio falls short in Phase III melanoma trial - FirstWord Pharma
IO Biotech Shares Climb Following Encouraging Cancer Vaccine Trial Results - MSN
Mixed results for IO Biotech's cancer vaccine Cylembio - The Pharma Letter
IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x - Stocktwits
IO Biotech drops after cancer vaccine narrowly misses main goal of late-stage study - TradingView
IO Biotech's Phase 3 Trial Fails To Deliver (NASDAQ:IOBT) - Seeking Alpha
IO Biotech's Skin Cancer Vaccine Combo Falls Short of Expectations, Seeks FDA Approval - AInvest
IO Biotech’s cancer vaccine shows improvement, but narrowly misses study goal - The Mighty 790 KFGO
Why Is IO Biotech Stock Falling Monday?IO Biotech (NASDAQ:IOBT) - Benzinga
IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval - European Biotechnology Magazine
Transcript : IO Biotech, Inc.Special Call - MarketScreener
Cancer vaccine’s ‘narrow’ phase 3 fail won’t stop IO heading to FDA - Fierce Biotech
Danish cancer vaccine just misses the mark in phase 3 trial - medwatch.com
Pharma Boom: What’s Up With IO Biotech? - timothysykes.com
IO Biotech's Cylembio: A Game-Changing Cancer Vaccine with Strong Clinical Signal and Regulatory Pathway Potential - AInvest
IO Biotech stock rises as cancer vaccine shows promising results By Investing.com - Investing.com Australia
IO Biotech stock rises as cancer vaccine shows promising results - Investing.com
IO Biotech Shares Jump in Premarket on Positive Melanoma Treatment Trial Data - MarketScreener
Navigating the Crossroads: IO Biotech's Cylembio and the Regulatory Hurdles of a Novel Cancer Vaccine - AInvest
IO Biotech Reveals Phase 3 Trial Results for Cylembio - TipRanks
IO Biotech stock jumps on data for cancer shot (IOBT:NASDAQ) - Seeking Alpha
IO Biotech's cancer vaccines shows improvement in late-stage study goal - MarketScreener
IO Biotech’s melanoma treatment shows improved survival rates - Investing.com India
IO Biotech’s melanoma treatment shows improved survival rates By Investing.com - Investing.com Canada
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Misse - The Manila Times
Clinical Trial Results: IO Biotech's Melanoma Drug Nearly Doubles Survival Time vs Standard Treatment - Stock Titan
Major Phase 3 Results Coming: IO Biotech's Novel Melanoma Treatment Could Challenge Standard of Care - Stock Titan
Will IO Biotech Inc. benefit from macro trendsWeekly Chart-Based Forecast for Traders - Newser
Identifying reversal signals in IO Biotech Inc.Free Stock Portfolio Allocation Guidance - Newser
Using fundamentals and technicals on IO Biotech Inc.Profitable Trading Blueprint with Entry Zones - Newser
Exit strategy if you’re trapped in IO Biotech Inc.Daily Exit and Entry Price Prediction - Newser
Custom watchlist performance reports with IO Biotech Inc.Entry Signal Generator with Risk Metrics - Newser
Regression analysis insights on IO Biotech Inc. performanceRisk/Reward Optimization Entry Point Analysis - Newser
Smart tools for monitoring IO Biotech Inc.’s price actionTechnical Trend Forecast for Investors - Newser
Forecasting IO Biotech Inc. price range with options dataSwing Trade Picks with High Potential - Newser
IO Biotech Stock (IOBT) Opinions on Phase 3 Clinical Trial Risks - Quiver Quantitative
IO Biotech to announce Phase 3 melanoma treatment results By Investing.com - Investing.com Canada
IO Biotech to announce Phase 3 melanoma treatment results - Investing.com
IO Biotech to Announce Pivotal Phase 3 Trial Results on August 11, 2025. - AInvest
0.91%
3.06%
자본화:
|
볼륨(24시간):